J A Kleinschmidt
Overview
Explore the profile of J A Kleinschmidt including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
59
Citations
2681
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Trepel M, Korbelin J, Spies E, Heckmann M, Hunger A, Fehse B, et al.
Gene Ther
. 2015 Oct;
22(10):848.
PMID: 26446851
No abstract available.
2.
Trepel M, Korbelin J, Spies E, Heckmann M, Hunger A, Fehse B, et al.
Gene Ther
. 2015 Jun;
22(10):840-7.
PMID: 26034897
Adeno-associated viral (AAV) vectors yield high potential for clinical gene therapy but, like for other vectors systems, they frequently do not sufficiently transduce the target tissue and their unspecific tropism...
3.
Varadi K, Michelfelder S, Korff T, Hecker M, Trepel M, Katus H, et al.
Gene Ther
. 2011 Sep;
19(8):800-9.
PMID: 21956692
We have demonstrated the potential of random peptide libraries displayed on adeno-associated virus (AAV)2 to select for AAV2 vectors with improved efficiency for cell type-directed gene transfer. AAV9, however, may...
4.
Sonntag F, Kother K, Schmidt K, Weghofer M, Raupp C, Nieto K, et al.
J Virol
. 2011 Sep;
85(23):12686-97.
PMID: 21917944
Adeno-associated virus type 2 (AAV2) capsid assembly requires the expression of a virally encoded assembly-activating protein (AAP). By providing AAP together with the capsid protein VP3, capsids are formed that...
5.
Ying Y, Muller O, Goehringer C, Leuchs B, Trepel M, Katus H, et al.
Gene Ther
. 2010 Apr;
17(8):980-90.
PMID: 20393510
Selection of targeted vectors from virus display peptide libraries is a versatile and efficient approach to improve vector specificity and efficiency. This strategy has been used to target various cell...
6.
Muller O, Schinkel S, Kleinschmidt J, Katus H, Bekeredjian R
Gene Ther
. 2008 Jul;
15(23):1558-65.
PMID: 18615116
Adeno-associated virus (AAV)-6 or -9-pseudotyped vectors are suitable for efficient cardiac gene transfer after intravenous injection in mice. However, a systemic application in larger animals or humans would require very...
7.
Kruger L, Eskerski H, Dinsart C, Cornelis J, Rommelaere J, Haberkorn U, et al.
Cancer Gene Ther
. 2008 Jan;
15(4):252-67.
PMID: 18202715
Autonomous parvoviruses possess an intrinsic oncotropism based on viral genetic elements controlling gene expression and genome replication. We constructed a hybrid vector consisting of the H1 parvovirus-derived expression cassette comprising...
8.
Raake P, Hinkel R, Muller S, Delker S, Kreuzpointner R, Kupatt C, et al.
Gene Ther
. 2007 Oct;
15(1):12-7.
PMID: 17943147
Cornerstone for an efficient cardiac gene therapy is the need for a vector system, which enables selective and long-term expression of the gene of interest. In rodent animal models adeno-associated...
9.
Huttner N, Girod A, Perabo L, Edbauer D, Kleinschmidt J, Buning H, et al.
Gene Ther
. 2003 Nov;
10(26):2139-47.
PMID: 14625569
The high prevalence of human serum antibodies against adeno-associated virus type 2 (AAV) vectors represents a potential limitation for in vivo applications. Consequently, the development of AAV vectors able to...
10.
Kern A, Schmidt K, Leder C, Muller O, Wobus C, Bettinger K, et al.
J Virol
. 2003 Sep;
77(20):11072-81.
PMID: 14512555
Infection of cells with adeno-associated virus (AAV) type 2 (AAV-2) is mediated by binding to heparan sulfate proteoglycan and can be competed by heparin. Mutational analysis of AAV-2 capsid proteins...